What is the current stock price of DBV Technologies S.A. (DBVT)?

As of the latest market data, DBV Technologies S.A. (DBVT) is trading at $20.59. The stock has seen a loss of -3.79% today.

Does DBV Technologies S.A. (DBVT) pay a dividend?

Based on current data, DBV Technologies S.A. does not have a confirmed active dividend policy.

What is the market cap of DBV Technologies S.A.?

The current market capitalization of DBV Technologies S.A. (DBVT) is approximately unavailable.

DBVT

DBV Technologies S.A.·Healthcare

20.59

3.785%(−0.81)

Market Closed

22.51

9.325%(+1.92)

After Hours

Last Updated: — ET

52W L: $7.0052W H: $26.18

DBVT NEWS

globenewswire.com

Apr 2

Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of March 31, 2026

defenseworld.net

Mar 29

DBV Technologies S.A. (NASDAQ:DBVT) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of DBV Technologies S.A. (NASDAQ: DBVT - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the nine ratings firms that are covering the firm, Marketbeat Ratings reports. Two research analysts have rated the stock with a sell recommendation, one has given a hold recommendation, four have assigned a buy recommendation

globenewswire.com

Mar 26

DBV Technologies Announces Filing of 2025 Annual Report on Form 10-K and Universal Registration Document

Châtillon, France, March 26, 2026 DBV Technologies Announces Filing of 2025 Annual Report on Form 10-K and Universal Registration Document DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a late-stage biopharmaceutical company (the “Company”), today announced the filing, for the year ended December 31, 2025, of its Annual Report on Form 10-K with the U.S. Securities and Exchange Commission (“SEC”) and its Universal Registration Document (“ 2025 URD”) with the French market authority, “Autorité des Marchés Financiers” (“AMF”). In compliance with French law, the following information are included in the 2025 URD : The 2025 annual financial report; The Board of Directors' corporate governance report (“rapport sur le gouvernement d'entreprise”) required under Article L.

globenewswire.com

Mar 26

DBV Technologies Reports Full Year 2025 Financial Results and Business Update

Châtillon, France, March 26, 2026 DBV Technologies Reports Full Year 2025 Financial Results and Business Update Continued advancing the VIASKIN® Peanut Patch clinical development programs in peanut-allergic toddlers (1 through 3 years old) and children (4 through 7 years old) Bolstered executive leadership team in preparation for BLA submission and potential approval Reported cash and cash equivalents of $194 million as of December 31, 2025, plus additional gross proceeds of $94 million received on January 16, 2026 —providing funding into the second quarter of 2027 DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Capital Market: DBVT) (the “Company”), a late-stage biopharmaceutical company, today reported financial results for the full year 2025. The consolidated financial statements are prepared under U.S. Generally Acceptable Accounting Principles (“U.S. GAAP”) and International Financial Reporting Standards (“IFRS”) for the purpose of Form 10-K and French “Document d'Enregistrement Universel” containing the Annual Financial Report – were approved by the Board of Directors on March 26, 2026.

globenewswire.com

Mar 24

DBV Technologies to Join CAC Mid 60 and SBF 120 Indices Following Euronext Paris Annual Review

Châtillon, France, March 24, 2026 DBV Technologies to Join CAC Mid 60 and SBF 120 Indices Following Euronext Paris Annual Review Changes went into effect on Monday, March 23, 2026 DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a late-stage biopharmaceutical company, today announced that following the annual review of the Euronext Paris indices on March 12, 2026, the Scientific Council of the Indices has admitted DBV to the CAC Mid 60 and SBF 120 Indices. The changes went into effect on Monday, March 23, 2026.

defenseworld.net

Mar 15

DBV Technologies (NASDAQ:DBVT) Shares Gap Up – Here’s What Happened

DBV Technologies S.A. (NASDAQ: DBVT - Get Free Report)'s share price gapped up before the market opened on Friday. The stock had previously closed at $20.06, but opened at $21.49. DBV Technologies shares last traded at $20.80, with a volume of 110,344 shares trading hands. Analyst Ratings Changes DBVT has been the subject of a

Company Profile

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents, and adults. The milk-induced company is also developing Viaskin Milk that is in Phase I/II clinical trial for the treatment of Immunoglobulin E (IgE) mediated cow's milk protein allergy (CMPA); Viaskin Egg, a pre-clinical stage product for the treatment of hen's egg allergy; and booster vaccine for Bordetella pertussis. Its other earlier stage research programs include a vaccine for the respiratory syncytial virus, as well as treatments for Crohn's disease, celiac disease, and type I diabetes. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.

Sector

Healthcare

Industry

Biotechnology

Employees

106

IPO Date

2014-10-22

Beta

-0.20

Websitewww.dbv-technologies.com↗